Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Xu, Xia ^a   Wang, Yan ^b   Wang, Fang ^c,d   Jia, Lizhou ^c   Zhou, Yiqin ^a   Deng, Fei ^a   Qu, Junwei ^a   Zhou, Bifang ^a   Meng, Aifeng ^a   Fu, Bole ^a   Chen, Xiaoxiang ^a,c,e   Qian, Zhiying ^a   Wang, Jinhua ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS   (United States)

^d GUANGZHOU MEDICAL UNIVERSITY   (China)

^e SOUTHEAST UNIVERSITY   (China)

Author keywords

CA 125; Epithelial ovarian cancer; HG SOC; Prognosis

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGED; ARTICLE; ASCITES; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVARY CANCER; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SECOND LOOK SURGERY; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 84876995445     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-31     Document Type: Article

References (35)

1. Cancer statistics, 2013. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2013 63 1 11 30 10.3322/caac.21166 23335087
2. Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five-year relative survival in the period 1978-2002. Hannibal CG, Acta Obstet Gynecol Scand 2008 87 12 1353 1360 10.1080/00016340802483000 18951210
3. Statistics on cancer in China: cancer registration in 2002. Yang L, Eur J Cancer Prev 2005 14 4 329 335 10.1097/00008469-200508000-00004 16030422 (Pubitemid 41104940)
4. The biology of ovarian cancer: new opportunities for translation. Bast RC Jr, Hennessy B, Mills GB, Nat Rev Cancer 2009 9 6 415 428 10.1038/nrc2644 19461667
5. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Shih Ie M, Kurman RJ, Am J Pathol 2004 164 5 1511 1518 10.1016/S0002-9440(10)63708-X 15111296 (Pubitemid 38529752)
6. Functional Polymorphisms of the hOGG1 Gene Confer Risk to Type 2 Epithelial Ovarian Cancer in Chinese. Chen X, Int J Gynecol Cancer 2011 21 8 1407 10.1097/IGC.0b013e31823122c6 21997177
7. New insights into ovarian cancer pathology. Prat J, Ann Oncol 2012 23 Suppl 10 111 x117 10.1093/annonc/mds300 22987944
8. Reactivity of a monoclonal antibody with human ovarian carcinoma. Bast RC Jr, J Clin Invest 1981 68 5 1331 1337 10.1172/JCI110380 7028788 (Pubitemid 12235035)
9. Early detection of ovarian cancer. Das PM, Bast RC Jr, Biomark Med 2008 2 3 291 303 10.2217/17520363.2.3.291 20477415
10. Role of tumour markers in monitoring epithelial ovarian cancer. Meyer T, Rustin GJ, Br J Cancer 2000 82 9 1535 1538 10789720 (Pubitemid 30204358)
11. Cancer antigen 125 and prognosis. Hogdall E, Curr Opin Obstet Gynecol 2008 20 1 4 8 10.1097/GCO.0b013e3282f2b124 18196998
12. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. Markman M, J Clin Oncol 2006 24 9 1454 1458 10.1200/JCO.2005.04.7373 16549840 (Pubitemid 46622013)
13. Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian cancer. Kang S, J Gynecol Oncol 2011 22 4 269 274 10.3802/jgo.2011.22.4.269 22247804
14. Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer. Kang S, Seo SS, Park SY, J Surg Oncol 2009 100 3 244 247 10.1002/jso.21258 19267361
15. Prognostic role of CA-125 nadir in stage IV epithelial ovarian cancer. Prat A, Parera M, Del Campo JM, J Clin Oncol 2008 26 10 1771 1772 author reply 1772 10.1200/JCO.2007.15.7594 18375912
16. Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Prat A, Ann Oncol 2008 19 2 327 331 10.1093/annonc/mdm495 18065408 (Pubitemid 351201715)
17. CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery. Wang F, J Ovarian Res 2013 6 1 14 10.1186/1757-2215-6-14 23402322
18. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Therasse P, J Natl Cancer Inst 2000 92 3 205 216 10.1093/jnci/92.3.205 10655437
19. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Rosen DG, Gynecol Oncol 2005 99 2 267 277 10.1016/j.ygyno.2005. 06.040 16061277 (Pubitemid 41502830)
20. An assessment of the value of serum CA 125 measurements in the management of epithelial ovarian carcinoma. Gard GB, Houghton CR, Gynecol Oncol 1994 53 3 283 289 10.1006/gyno.1994.1135 8206399 (Pubitemid 24187854)
21. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Juretzka MM, Gynecol Oncol 2007 104 1 176 180 10.1016/j.ygyno.2006.07.027 16996584 (Pubitemid 46054121)
22. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study. van Altena AM, Gynecol Oncol 2010 119 2 265 269 10.1016/j.ygyno.2010.07.025 20797777
23. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer. Kim HS, Acta Obstet Gynecol Scand 2008 87 11 1136 1142 10.1080/00016340802478158 18951217
24. Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Crawford SM, Peace J, Ann Oncol 2005 16 1 47 50 10.1093/annonc/mdi012 15598937 (Pubitemid 40124477)
25. The second-look operation improves survival in suboptimally debulked stage III ovarian cancer patients. Rahaman J, Int J Gynecol Cancer 2005 15 1 19 25 10.1111/j.1048-891X.2005.15003.x 15670292 (Pubitemid 40194328)
26. Analysis of the results and long-term follow-up of second-look laparotomy in advanced ovarian cancer. Sawicki S, Eur J Gynaecol Oncol 2009 30 4 422 425 19761136
27. [Follow-up of 70 patients with advanced ovarian cancer after negative second-look laparotomy]. Kojs Z, J Gynecol Obstet Biol Reprod (Paris) 2006 35 1 16 22 10.1016/S0368-2315(06)76367-0 (Pubitemid 43205737)
28. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study. Greer BE, Gynecol Oncol 2005 99 1 71 79 10.1016/j.ygyno.2005.05.012 16039699 (Pubitemid 41354585)
29. Second-look operation improves survival in suboptimal, debulked, stage III ovarian cancer. Escobar PF, Michener CM, Rose PG, Int J Gynecol Cancer 2005 15 6 1258 author reply 1259 10.1111/j.1525-1438.2005.00272.x 16343227 (Pubitemid 43110197)
30. [The correlation between prognostic factors and outcome of second look laparotomy in ovarian cancer]. Dudziak M, Ginekol Pol 2005 76 7 555 563 16363382
31. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Bast RC Jr, Cancer 2010 116 12 2850 2853 10.1002/cncr.25203 20564390
32. Serum CA 125 levels in epithelial ovarian cancer: relation with findings at second-look operations and their role in the detection of tumour recurrence. Schilthuis MS, Br J Obstet Gynaecol 1987 94 3 202 207 10.1111/j.1471-0528.1987. tb02354.x 3471274 (Pubitemid 17036898)
33. Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. Prat A, Ann Oncol 2009 20 2 294 297 18820245
34. Bevacizumab combination therapy: for the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Dhillon S, Drugs 2012 72 7 917 930 10.2165/11208940-000000000-00000 22515620
35. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Stark D, Lancet Oncol 2013 14 3 236 243 10.1016/S1470-2045(12)70567-3 23333117